Serabelisib

色雷利塞

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameSerabelisib
Drug Alias NameMLN-1117INK-1117TAK-117ART-001PETRA-06 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsSolid tumoursVascular MalformationsHepatic Insufficiency +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntellikine Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co LtdKaken Pharmaceutical Co Ltd
Inactive CompaniesPetra PharmaFaeth Therapeutics IncMillennium Pharmaceuticals Inc
Active IndicationsVascular MalformationsHepatic InsufficiencyTriple Negative Breast Neoplasms
Inactive IndicationsSolid tumoursNeoplasm MetastasisEndometrial Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksN/A